Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors

被引：22

作者：

Andres, Jose-Ignacio ^{[1
]}

Buijnsters, Peter ^{[2
]}

De Angelis, Meri ^{[1
]}

Langlois, Xavier ^{[3
]}

Rombouts, Frederik ^{[2
]}

Trabanco, Andres A. ^{[1
]}

Vanhoof, Greet ^{[4
]}

机构：

[1] Janssen Cilag SA, Janssen Res & Dev, Toledo 45007, Spain

[2] Janssen Pharmaceut NV, Janssen Res & Dev, Neurosci Med Chem, B-2340 Beerse, Belgium

[3] Janssen Pharmaceut NV, Janssen Res & Dev, Neurosci Biol, B-2340 Beerse, Belgium

[4] Janssen Pharmaceut NV, Janssen Res & Dev, CREATe, Translat Sci, B-2340 Beerse, Belgium

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 03期

关键词：

Neurological disorders; PDE2; inhibitors; PDE10; Triazoloquinoxalines; CGMP; PDE10A; CAMP; RAT; STRIATUM; MEMORY; BRAIN;

D O I：

10.1016/j.bmcl.2012.11.077

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The synthesis, preliminary evaluation and structure-activity relationship (SAR) of a series of 1-aryl-4-methyl[1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors are described. From this investigation compound 31 was identified, showing good combined potency, acceptable brain uptake and high selectivity for both PDE2 and PDE10 enzymes. Compound 31 was subjected to a microdosing experiment in rats, showing preferential distribution in brain areas where both PDE2 and PDE10 are highly expressed. These promising results may drive the further development of highly potent combined PDE2/PDE10 inhibitors, or even of selective inhibitors of PDE2 and/or PDE10. (c) 2012 Elsevier Ltd. All rights reserved.

引用

页码：785 / 790

页数：6

共 50 条

[1] Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors
Rombouts, Frederik J. R.
Tresadern, Gary
Buijnsters, Peter
Langlois, Xavier
Tovar, Fulgencio
Steinbrecher, Thomas B.
Vanhoof, Greet
Somers, Marijke
Andres, Jose-Ignacio
Trabanco, Andres A.
ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (03): : 282 - 286
[2] Discovery of phosphodiesterase-10 (PDE10) inhibitors for the treatment of schizophrenia
Raheem, Izzat T.
Barrow, Jim
Bednar, Rodney A.
Breslin, Michael J.
Bruno, Joseph
Cofre, Victoria
Coleman, Paul J.
Fandozzi, Christine
Fuerst, Joy
Gold, Lisa
Hill, Nicole
Hutson, Pete H.
Huszar, Sarah
Kandebo, Monika
Kemmerer, Amanda
Kim, Somang H.
Krishnan, Raghu
Lemaire, Wei
Ma, Bennett
McGaughey, Georgia
Munshi, Sanjeev
Shannon Nguyen
Parmentier-Batteur, Sophie
Schreier, John D.
Sharma, Sujata
Shipe, William D.
Smith, Sean
Uslaner, Jason
Yan, Youwei
Cox, Christopher D.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
[3] Discovery of phosphodiesterase-10 (PDE10) inhibitors for the treatment of schizophrenia
Raheem, Izzat T.
Barrow, Jim
Bednar, Rodney A.
Breslin, Michael J.
Bruno, Joseph
Cofre, Victoria
Coleman, Paul J.
Fandozzi, Christine
Fuerst, Joy
Gold, Lisa
Hill, Nicole
Hutson, Pete H.
Huszar, Sarah
Kandebo, Monika
Kemmerer, Amanda L.
Kim, Somang H.
Krishnan, Raghu
Lemaire, Wei
Ma, Bennett
McGaughey, Georgia
Munshi, Sanjeev
Nguyen, Shannon
Parmentier-Batteur, Sophie
Schreier, John D.
Sharma, Sujata
Shipe, William D.
Smith, Sean
Uslaner, Jason
Yan, Youwei
Cox, Christopher D.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
[4] Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, Part I: Transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors
Plummer, Mark S.
Cornicelli, Joseph
Roark, Howard
Skalitzky, Donald J.
Stankovic, Charles J.
Bove, Susan
Pandit, Jayvardhan
Goodman, Annise
Hicks, James
Shahripour, Aurash
Beidler, David
Lu, Xiao Kang
Sanchez, Brian
Whitehead, Christopher
Sarver, Ron
Braden, Timothy
Gowan, Richard
Shen, Xi Qiang
Welch, Katherine
Ogden, Adam
Sadagopan, Nalini
Baum, Heidi
Miller, Howard
Banotai, Craig
Spessard, Cindy
Lightle, Sandra
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (11) : 3438 - 3442
[5] Selective Inhibitors of PDE2, PDE9, and PDE10: Modulators of Activity of the Central Nervous System
Jorgensen, Morten
Kehler, Jan
Langgard, Morten
Svenstrup, Niels
Tagmose, Lena
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 48, 2013, 48 : 37 - 55
[6] Inhibition of PDE2, PDE5 and PDE10: Effects on short-term memory
Reneerkens, O. A. H.
Rutten, K.
Sik, A.
Blokland, A.
Steckler, T.
Steinbusch, H. W. M.
Prickaerts, J.
BEHAVIOURAL PHARMACOLOGY, 2008, 19 (5-6): : 670 - 670
[7] [1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains
Fedorov, Oleg
Lingard, Hannah
Wells, Chris
Monteiro, Octovia P.
Picaud, Sarah
Keates, Tracy
Yapp, Clarence
Philpott, Martin
Martin, Sarah J.
Felletar, Ildiko
Marsden, Brian D.
Filippakopoulos, Panagis
Mueller, Susanne
Knapp, Stefan
Brennan, Paul E.
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (02) : 462 - 476
[8] Quinoxaline derivatives part II: Synthesis and antimicrobial testing of 1,2,4-triazolo[4,3-a]quinoxalines, 1,2,4-triazino[4,3-a]quinoxalines and 2-pyrazolylquinoxalines
El-Hawash, SA
Habib, NS
Fanaki, NH
PHARMAZIE, 1999, 54 (11): : 808 - 813
[9] PDE2 and PDE10, but not PDE5, inhibition affect basic auditory information processing in rats
Reneerkens, O. A. H.
Sambeth, A.
Blokland, A.
Prickaerts, J.
BEHAVIOURAL BRAIN RESEARCH, 2013, 250 : 251 - 256
[10] Discovery of new orally active phosphodiesterase (PDE4) inhibitors
Ochiai, H
Ishida, A
Ohtani, T
Kusumi, K
Kishikawa, K
Yamamoto, S
Takeda, H
Obata, T
Nakai, H
Toda, M
CHEMICAL & PHARMACEUTICAL BULLETIN, 2004, 52 (09) : 1098 - 1104

← 1 2 3 4 5 →